Global Partnerships for Sickle Cell Disease (SCD): Advancing Science and Technology in Health in Africa

SC Intelligence in Science (ISC) in collaboration with the Muhimbili University of Health and Allied Sciences (MUHAS) - SickleInAfrica and the Tanzanian Embassy to the United States of America, will hold a scientific session to address Sickle Cell Disease (SCD) at the US-Africa Leaders summit on  Tuesday, 13 Dec, 2022 9am to 12:30pm EDT, 05pm to 08:30pm EAT (Save the date)

Science Series: Session II -13039: Global Partnerships for Sickle Cell Disease (SCD): Advancing Science and Technology in Health in Africa

See more details for the session here;

Register at: https://scienceusafricaleaders.sched.com/  

***************************************************************************************************
Key Objectives. The session will focus on

1. Partnerships in education and training to foster institutional collaborations that allow for basic and advanced training opportunities such as Postdoctoral fellowships and faculty exchanges.

2. Discuss the strategy for financing and investing in scientific research and the translation of discoveries to improve care for patients with SCD, focusing on advancing curative therapies like gene therapy and bone marrow transplantation.

3. Showcase the need for strengthening pre-existing manufacturing infrastructures in the continent and scaling up through meaningful collaborations in which complementary areas of expertise can be merged, resources combined, and risks shared to support sustainable local production of medicines such as Hydroxyurea.

4. Elucidate the critical role of politicians and policy-makers in developing and implementing policies to address SCD through sustainable strategies for prevention, diagnosis, and comprehensive and curative healthcare.

Target audience

Multi-disciplinary stakeholders are working to address SCD at country, regional, and global levels. Participants are anticipated to include scientists, patient advocates, healthcare providers, policy-makers and other government officials, researchers, Industry, NGOs, philanthropies, and multilateral health and research organizations.